290 related articles for article (PubMed ID: 32804976)
1. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
Lowe AJ; Sjödin S; Rodrigues FB; Byrne LM; Blennow K; Tortelli R; Zetterberg H; Wild EJ
PLoS One; 2020; 15(8):e0233820. PubMed ID: 32804976
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
[TBL] [Abstract][Full Text] [Related]
4. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease.
Armstrong A; Mattsson N; Appelqvist H; Janefjord C; Sandin L; Agholme L; Olsson B; Svensson S; Blennow K; Zetterberg H; Kågedal K
Neuromolecular Med; 2014 Mar; 16(1):150-60. PubMed ID: 24101586
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and Motor Norms for Huntington's Disease.
Mills JA; Long JD; Mohan A; Ware JJ; Sampaio C
Arch Clin Neuropsychol; 2020 Aug; 35(6):671-682. PubMed ID: 32407458
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
9. Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington's Disease.
Kolenc M; Kobal J; Podnar S
J Huntingtons Dis; 2017; 6(2):105-113. PubMed ID: 28482643
[TBL] [Abstract][Full Text] [Related]
10. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
Niemelä V; Landtblom AM; Blennow K; Sundblom J
PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
[TBL] [Abstract][Full Text] [Related]
11. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
[TBL] [Abstract][Full Text] [Related]
12. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
[TBL] [Abstract][Full Text] [Related]
13. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of dystonia in adult patients with Huntington's disease.
van de Zande NA; Massey TH; McLauchlan D; Pryce Roberts A; Zutt R; Wardle M; Payne GC; Clenaghan C; Tijssen MAJ; Rosser AE; Peall KJ
Eur J Neurol; 2017 Sep; 24(9):1140-1147. PubMed ID: 28661018
[TBL] [Abstract][Full Text] [Related]
15. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.
Rodrigues FB; Byrne LM; Lowe AJ; Tortelli R; Heins M; Flik G; Johnson EB; De Vita E; Scahill RI; Giorgini F; Wild EJ
J Neurochem; 2021 Jul; 158(2):539-553. PubMed ID: 33797782
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease.
Korpela S; Sundblom J; Zetterberg H; Constantinescu R; Svenningsson P; Paucar M; Niemelä V
J Neurol Sci; 2024 Apr; 459():122979. PubMed ID: 38569376
[TBL] [Abstract][Full Text] [Related]
17. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; De Vita E; Blennow K; Scahill R; Zetterberg H; Heslegrave A; Wild EJ
Sci Rep; 2018 Mar; 8(1):4260. PubMed ID: 29523800
[TBL] [Abstract][Full Text] [Related]
19. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
Fodale V; Boggio R; Daldin M; Cariulo C; Spiezia MC; Byrne LM; Leavitt BR; Wild EJ; Macdonald D; Weiss A; Bresciani A
J Huntingtons Dis; 2017; 6(4):349-361. PubMed ID: 29125493
[TBL] [Abstract][Full Text] [Related]
20. Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers.
Li F; Li K; Li C; Luo S;
J Huntingtons Dis; 2019; 8(3):323-332. PubMed ID: 31256145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
